Synthesis, cytotoxicity evaluation, molecular docking and utility of novel chalcones as precursors for heterocycles incorporating pyrazole moiety
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Gomha S.M. | |
dc.contributor.author | Abdallah M.A. | |
dc.contributor.author | Abbas I.M. | |
dc.contributor.author | Kazem M.S.H. | |
dc.contributor.other | Department of Chemistry | |
dc.contributor.other | Faculty of Science | |
dc.contributor.other | Cairo University | |
dc.contributor.other | Giza | |
dc.contributor.other | 12613 | |
dc.contributor.other | Egypt; Department of Chemistry | |
dc.contributor.other | Faculty of Dentistry | |
dc.contributor.other | October University for Modern Science & Arts University | |
dc.contributor.other | Giza | |
dc.contributor.other | 12613 | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:03Z | |
dc.date.available | 2020-01-09T20:41:03Z | |
dc.date.issued | 2018 | |
dc.description | Scopus | |
dc.description.abstract | Background: Chalcones, 2-pyrazolines and thiazoles have been reported to possess various pharmacological activities. Objective: Synthesis of new chalcones and utilizing them as a building block for constructing a series of thiazole derivatives and evaluating some of them as anticancer agents. Method: The new compounds were synthesized via stirring at room temperature or thermal heating. Cytotoxic evaluation of the new synthesized compounds was tested using the method of Skehan et al. Moreover, the computational studies were performed using MOE 2014.09 software. Result: A series of new chalcones were prepared by the reaction of ethyl 3-acetyl-1-aryl-5-methyl- 1H-pyrazole-4-carboxylate with a number of substituted benzaldehydes. One of these chalcones was used as a building block for constructing a pyrazoline ring via its reaction with thiosemicarbazide. The produced carbothioamide derivative was used for the preparation of two series of thiazole derivatives by its reaction with a number of hydrazonoyl chlorides. Moreover, reaction of 3- acetylpyrazole thiosemicarbazone derivative with a number of N-aryl-2-oxopropane hydrazonoyl chlorides afforded 5-arylazothiazole derivatives. The assigned structures for all the newly synthesized compounds were confirmed on the basis of elemental analyses and spectral data. Some of the newly synthesized chalcones and thiazoles were tested for their cytotoxicity against human colon carcinoma cell line (HCT-116) and the molecular docking was carried out on the most active compound 3f. Conclusion: The results of the anticancer activity revealed that compounds 3f, 3e, 3c and 3b have promising activities compared with the standard drug Doxorubicin. Moreover, the computational studies confirm the results of biological activity. Also, the ADME profile study showed that compound 3f can be considered as a promising drug by conducting good pharmacokinetic and medicinal chemistry tests. � 2018 Bentham Science Publishers. | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=4700152603&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.2174/1573406413666171020114105 | |
dc.identifier.doi | PubMed ID : 29065841 | |
dc.identifier.issn | 15734064 | |
dc.identifier.other | https://doi.org/10.2174/1573406413666171020114105 | |
dc.identifier.other | PubMed ID : 29065841 | |
dc.identifier.uri | https://t.ly/BXXPB | |
dc.language.iso | English | en_US |
dc.publisher | Bentham Science Publishers B.V. | en_US |
dc.relation.ispartofseries | Medicinal Chemistry | |
dc.relation.ispartofseries | 14 | |
dc.subject | ADME study | en_US |
dc.subject | Chalcones | en_US |
dc.subject | Cytotoxicity evaluation | en_US |
dc.subject | Hydrazonoyl halides | en_US |
dc.subject | Molecular docking | en_US |
dc.subject | Pyrazolines | en_US |
dc.subject | Thiazoles | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | chalcone derivative | en_US |
dc.subject | diethyl 3,3' [3,3' (1,4 phenylene)bis(acryloyl)bis(5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | ethyl 1 (4 chlorophenyl) 3 cinnamoyl 5 methyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 1 (4 chlorophenyl) 3 [3 (4 chlorophenyl)acryloyl] 5 methyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 1 (4 chlorophenyl) 3 [3 (4 methoxyphenyl)acryloyl] 5 methyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 1' carbamothioyl 5 methyl 1,5' diphenyl 4',5' dihydro 1h,1'h [3,3' bipyrazole] 4 carboxylate | en_US |
dc.subject | ethyl 1' [5 [(4 chlorophenyl)diazenyl] 4 methylthiazol 2 yl] 5 methyl 1,5' diphenyl 4',5' dihydro 1h,1'h [3,3' bipyrazole] 4 carboxylate | en_US |
dc.subject | ethyl 1' [5 [2 (4 chlorophenyl)hydrazono] 4 oxo 4,5 dihydrothiazol 2 yl] 5 methyl 1,5' diphenyl 4',5' dihydro 1h,1'h [3,4' bipyrazole] 4 carboxylate | en_US |
dc.subject | ethyl 3 cinnamoyl 5 methyl 1 (4 nitrophenyl) 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 cinnamoyl 5 methyl 1 (4 tolyl) 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 cinnamoyl 5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [1 (2 carbamothioylhydrazono)ethyl] 5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [1 [2 [5 [(4 chlorophenyl)diazenyl] 4 methylthiazol 2 yl]hydrazono]ethyl] 5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [3 (4 chlorophenyl)acryloyl] 5 methyl 1 (4 nitrophenyl) 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [3 (4 chlorophenyl)acryloyl] 5 methyl 1 (4 tolyl) 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [3 (4 chlorophenyl)acryloyl] 5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [3 (4 methoxyphenyl)acryloyl] 5 methyl 1 (4 nitrophenyl) 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 3 [3 (4 methoxyphenyl)acryloyl] 5 methyl 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 1 (4 tolyl) 3 [3 (4 tolyl)acryloyl] 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 1 phenyl 3 [3 (4 tolyl)acryloyl] 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 1' [4 methyl 5 (phenyldiazenyl)thiazol 2 yl] 1,5' diphenyl 4',5' dihydro 1h,1'h [3,3' bipyrazole] 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 1' [4 oxo 5 (2 phenylhydrazono) 4,5 dihydrothiazol 2 yl] 1,5' diphenyl 4',5' dihydro 1h,1'h [3,3' bipyrazole] 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 3 [1 [2 [4 methyl 5 (4 tolyldiazenyl)thiazol 2 yl]hydrazono]ethyl] 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | ethyl 5 methyl 3 [1 [2 [4 methyl 5 (phenyldiazenyl)thiazol 2 yl]hydrazono]ethyl] 1 phenyl 1h pyrazole 4 carboxylate | en_US |
dc.subject | heterocyclic compound | en_US |
dc.subject | pyrazole derivative | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | chalcone derivative | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | phosphodiesterase inhibitor | en_US |
dc.subject | pyrazole derivative | en_US |
dc.subject | thiazole derivative | en_US |
dc.subject | thiosemicarbazone derivative | en_US |
dc.subject | antineoplastic activity | en_US |
dc.subject | Article | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug cytotoxicity | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | elemental analysis | en_US |
dc.subject | HCT 116 cell line | en_US |
dc.subject | human | en_US |
dc.subject | human cell | en_US |
dc.subject | molecular docking | en_US |
dc.subject | priority journal | en_US |
dc.subject | structure activity relation | en_US |
dc.subject | chemistry | en_US |
dc.subject | drug screening | en_US |
dc.subject | molecular docking | en_US |
dc.subject | synthesis | en_US |
dc.subject | Antineoplastic Agents | en_US |
dc.subject | Chalcones | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | Drug Screening Assays, Antitumor | en_US |
dc.subject | HCT116 Cells | en_US |
dc.subject | Humans | en_US |
dc.subject | Molecular Docking Simulation | en_US |
dc.subject | Phosphodiesterase Inhibitors | en_US |
dc.subject | Pyrazoles | en_US |
dc.subject | Structure-Activity Relationship | en_US |
dc.subject | Thiazoles | en_US |
dc.subject | Thiosemicarbazones | en_US |
dc.title | Synthesis, cytotoxicity evaluation, molecular docking and utility of novel chalcones as precursors for heterocycles incorporating pyrazole moiety | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Nowakowaska, Z., Kedzia, B., Schroeder, G., Synthesis, physicochemical properties and antimicrobial evaluation of new (E)- chalcones (2008) Eur. J. Med. Chem., 43, pp. 707-713; Maayan, S., Ohad, N., Soliman, K., Chalcones as potent tyrosinase inhibitors: The importance of a 2,4-substituted resorcinol moiety (2005) Bioorg. Med. Chem., 13, pp. 433-441; Abdallah, M.A., Gomha, S.M., Abdelaziz, M., Serag, N., Synthesis and antiviral evaluation of some novel thiazoles and 1,3-thiazines substituted with pyrazole moiety against rabies virus (2016) Turk. J. Chem., 40, pp. 441-453; El-Hashash, M.A., Gomha, S.M., El-Arab, E.E., Utility of pyrazolylchalcone synthon to synthesize azolopyrimidines under grindstone technology (2017) Chem. Pharm. Bull., 65, pp. 90-96; Satyanarayana, M., Tiwari, P., Tripathi, B.K., Srivastava, A.K., Pratap, R., Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines (2004) Bioorg. Med. Chem., 12, pp. 883-889; Nakagawa, G., Lee, K., Anti-AIDS agents 68. The first total synthesis of a unique potent anti-HIV chalcone from genus Desmos (2006) Tetrahedron Lett., 47, pp. 8263-8266; Dominguez, J.N., Leon, C., Rodrigues, J., Rosenthal, P.J., Synthesis and antimalarial activity of sulfonamide chalcone derivatives (2005) Farmaco, 60, pp. 307-311; Secci, D., Carradori, S., Bolasco, A., Bizzarri, B., D�Ascenzio, M., Maccioni, E., Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors (2012) Curr. Topics Med. Chem., 12, pp. 2240-2257; Ozdemir, A., Turan-Zitouni, G., Kaplanckl, Z.A., Revial, G., Guven, K., Synthesis and antimicrobial activity of 1-(4-aryl-2- thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives (2007) Eur. J. Med. Chem., 42, pp. 403-409; Abid, M., Azam, A., Synthesis, characterization and antimoebic activity of 1-(thiazolo[4,5-b]quinoxalin-2-yl)-3-phenyl-2-pyrazoline derivatives (2006) Bioorg. Med. Chem. Lett., 16, pp. 2812-2816; Gomha, S.M., Riyadh, S.M., Abdalla, M.M., Solvent-drop grinding method: Efficient synthesis, DPPH radical scavenging and antidiabetic activities of chalcones, bis-chalcones, azolines, and bisazolines (2015) Curr. Org. Synth., 12, pp. 220-228; Flora, F., Hosni, H.H., Girgis, A.S., Novel bis (1-acyl-2- pyrazolines) of potential anti-inflammatory and molluscicidal properties (2006) Bioorg. Med. Chem., 14, pp. 3929-3937; Kreutzberger, A., Kolter, K., Antiviral agents XXVII: Aminomethynylation of 5-oxo-2-pyrazoline-3-carboxylic acid derivatives (1986) Arch. Pharm., 319, pp. 18-25; Gomha, S.M., Abdallah, M.A., Abdelaziz, M., Serag, N., Ecofriendly one-pot synthesis and antiviral evaluation of pyrazolyl chalcones and pyrazolines of medicinal interest (2016) Turk. J. Chem., 40, pp. 484-498; Shaharyar, M., Siddiqui, A.A., Ali, M.M., Sriram, D., Yogeeswari, P., Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(-4--hydroxy-3--methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines (2006) Bioorg. Med. Chem. Lett., 16, pp. 3947-3949; Ozdemir, Z., Kandilci, H.B., Gumusel, B., Calis, U., Bilgin, A., A. Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives (2007) Eur. J. Med. Chem., 42, pp. 373-379; Amir, M., Kumar, H., Khan, S.A., Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents (2008) Bioorg. Med. Chem. Lett., 18, pp. 918-922; Gomha, S.M., Ahmed, S.M., Abdelhamid, A.O., Synthesis and cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-one incorporating triazole moiety (2015) Molecules, 20, pp. 1357-1376; Gomha, S.M., Abdel-Aziz, H.A., Synthesis of new heterocycles derived from 3-(3-methyl-1H-indol-2-yl)-3-oxopropanenitrile as potent antifungal agents (2012) Bull. Korean Chem. Soc., 33, pp. 2985-2990; Gomha, S.M., Khalil, K.D., A convenient ultrasound-promoted synthesis and cytotoxic activity of some new thiazole derivatives bearing a coumarin nucleus (2012) Molecules, 17, pp. 9335-9347; Karegoudar, P., Karthikeyan, M.S., Prasad, D.J., Mahalinga, M., Holla, B.S., Kumari, N.S., Synthesis of some novel 2,4-disubstituted thiazoles as possible antimicrobial agents (2008) Eur. J. Med. Chem., 43, pp. 261-267; Cukurovali, A., Yilmaz, I., Gur, S., Kazaz, C., Synthesis, antibacterial and antifungal activity of some new thiazolylhydrazone derivatives containing 3-substituted cyclobutane ring (2006) Eur. J. Med. Chem., 41, pp. 201-207; Gomha, S.M., Riyadh, S.M., Abbas, I.M., Bauomi, M.A., Synthetic utility of ethylidenethio- semicarbazide: Synthesis and anti-cancer activity of 1,3-thiazines and thiazoles with imidazole moiety (2013) Heterocycles, 87, pp. 341-356; Shih, M.H., Ying, K.F., Syntheses and evaluation of antioxidant activity of sydnonyl substituted thiazolidinone and thiazoline derivatives (2004) Bioorg. Med. Chem., 12, pp. 4633-4643; Shiradkar, M., Kumar, G.V.S., Dasari, V., Tatikonda, S., Akula, K.C., Shah, R., Clubbed triazoles: A novel approach to antitubercular drugs (2007) Eur. J. Med. Chem., 42, pp. 807-816; Gomha, S.M., Badrey, M.G., A convenient synthesis of some new thiazoles and pyrimidine derivatives incorporating naphthalene moiety (2013) J. Chem. Res., 37, pp. 86-90; Chimenti, F., Secci, D., Bolasco, A., Chimenti, P., Granese, A., Carradori, S., D�Ascenzio, M., Orallo, F., Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones (2010) Med. Chem. Commun., 1, pp. 61-72; Abbas, I.M., Riyadh, S.M., Abdallah, M.A., Gomha, S.M., A novel route to tetracyclic fused tetrazines and thiadiazines (2006) J. Heterocycl. Chem., 43, pp. 935-942; Gomha, S.M., Eldebss, T.M.A., Abdulla, M.M., Mayhoub, A.S., Diphenylpyrroles: Novel p53 activators (2014) Eur. J. Med. Chem., 82, pp. 472-479; Gomha, S.M., Khalil, K.D., El-Zanate, A.M., Riyadh, S.M., A facile green synthesis and anti-cancer activity of bis-arylhydrazononitriles, triazolo[5,1-c][1,2,4]triazine, and 1,3,4-thiadiazoline (2013) Heterocycles, 87, pp. 1109-1120; Gomha, S.M., Dawood, K.M., Synthesis of novel indolizine, pyrrolo[1,2-a]quinoline, and 4,5-dihydrothiophene derivatives via nitrogen ylides and their antimicrobial evaluation (2014) J. Chem. Res., 38, pp. 515-519; Gomha, S.M., Abdelaziz, M.R., Abdel-aziz, H.M., Hassan, S.A., Green synthesis and molecular docking of thiazolyl-thiazole derivatives as potential cytotoxic agents (2017) Mini-Rev. Med. Chem., 17, pp. 805-815; Gomha, S.M., A facile one-pot synthesis of 6,7,8,9-tetrahydrobenzo[ 4,5]thieno[2,3-d]-1,2,4-triazolo[4,5-a]pyrimidin-5-ones (2009) Monatsh. Chem., 140, pp. 213-220; Abbas, I.M., Gomha, S.M., Elaasser, M.M., Bauomi, M.A., Synthesis and biological evaluation of new pyridines containing imidazole moiety as antimicrobial and anticancer agents (2015) Turk. J. Chem., 39, pp. 334-346; Gomha, S.M., Abdel-aziz, H.M., Khalil, K.D., Synthesis and SAR study of the novel thiadiazole-imidazole derivatives as new anticancer agents (2016) Chem. Pharm. Bull., 64, pp. 1356-1363; Gomha, S.M., Abbas, I.M., Elaasser, M.M., Mabrouk, B.K.A., Synthesis, molecular docking and pharmacological study of pyrimido-thiadiazinones and its bis-derivatives (2017) Lett. Drug Des. Disc., 14, pp. 434-443; Gomha, S.M., Eldebss, T.M.A., Badrey, M.G., Abdulla, M.M., Mayhoub, A.S., Novel 4-heteroaryl-antipyrines as DPP-IV Inhibitors (2015) Chem. Biol. Drug Des., 86, pp. 1292-1303; Attanasi, O.A., Fitippone, P., Fiorucci, C., Mantellini, F., Aspects of the chemistry of functionalized 1-phenylpyrazoles available from 1,2-diaza-l,3-butadienes and 2-phenylazo-l,3-dicarbonyl compounds (1999) Tetrahedron Lett., 40, pp. 3891-3894; Gomha, S.M., Salah, T.A., Abdelhamid, A.O., Synthesis, characterization and pharmacological evaluation of some novel thiadiazoles and thiazoles incorporating pyrazole moiety as potent anticancer agents (2015) Monatsh. Chem., 146, pp. 149-158; Gomha, S.M., Edrees, M.M., Altalbawy, F.M.A., Synthesis and characterization of some new bis-pyrazolyl-thiazoles incorporating the thiophene moiety as potent anti-tumor agents (2016) Inter. J. Mol. Sci., 17, p. E1499. , pii; Shawali, A.S., Gomha, S.M., A new entry for short and regioselective synthesis of [1,2,4]triazolo[4,3-b][1,2,4]-triazin-7(1H)-one (2000) Adv. Synth. Catal., 342, pp. 599-604; Strada, S.J., Uzunov, P., Weiss, B., Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain (1974) J. Neurochem., 23, pp. 1097-1103; Sung, B.J., Hwang, K.Y., Jeon, Y.H., Lee, J.I., Heo, Y.S., Kim, J.H., Moon, J., Cho, J.M., Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules (2003) Nature, 425, pp. 98-102; Card, G.L., Blasdel, L., England, B.P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Zhang, K.Y.J., A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design (2005) Nat. Biotech., 23, pp. 201-207; Madeswaran, A., Umamaheswari, M., Kkumar, K.A., Sivashanmugam, T., Subhadradevi, V., Jagannath, P., Insilico docking studies of phosphodiesterase inhibitory activity of commercially available flavonoids (2012) Orient. Pharm. Exp. Med., 12, pp. 301-306; Ertl, P., Rohde, B., Selzer, P., Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties (2000) J. Med. Chem., 43, pp. 3714-3717; Potts, R.O., Guy, R.H., Predicting skin permeability (1992) Pharm. Res., 9, pp. 663-669; Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (2001) Adv. Drug Deliv. Rev., 46, pp. 3-26; Baell, J.B., Holloway, G.A., New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays (2010) J. Med. Chem., 53, pp. 2719-2740; Teague, S.J., Davis, A.M., Leeson, P.D., Oprea, T., The Design of Leadlike Combinatorial Libraries (1999) Angew Chem. Int. Ed. Engl., 38, pp. 3743-3748; Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.I., Boyd, M.R., New colorimetric cytotoxicity assay for anticancer-drug screening (1990) J. Nat. Cancer Inst., 82, pp. 1107-1112 | |
dcterms.source | Scopus |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- avatar_scholar_256.png
- Size:
- 6.31 KB
- Format:
- Portable Network Graphics
- Description: